title: Chronotropic cardiac effects of falipamil in conscious dogs: interactions with the autonomic nervous system and various ionic conductances.
abstract: The chronotropic cardiac effects of falipamil were studied in conscious dogs with chronic atrioventricular (AV) block. Falipamil (0.5-2 mg/kg) initially increased atrial rate dose dependently. After atropine and atropine-pindolol, falipamil (2 mg/kg) decreased atrial rate, but after pindolol, it did not modify atrial rate. After atropine-pindolol-phenoxybenzamine, atropine-pindolol-yohimbine, atropine-pindolol-verapamil, and atropine-pindolol-quinidine pretreatment, falipamil produced atrial bradycardia. Falipamil dose-relatedly decreased ventricular rate. Falipamil (2 mg/kg) decreased ventricular rate after atropine, pindolol, and atropine-pindolol more than under basal conditions. After the other four pretreatments, it also produced ventricular bradycardia. Falipamil did not affect mean blood pressure (MBP) at any dose. These results (a) show that the initial atrial cardio-acceleration produced by falipamil results from its direct vagolytic action; (b) show that absence of atrial bradycardia results from buffering by the vagolytic effect and/or a relatively low basal atrial rate; (c) suggest that the falipamil ventricular bradycardia is partly buffered by the vagolytic effect, norepinephrine (NE) release, and involvement of alpha 2-adrenoceptors; (d) exclude involvement of postsynaptic muscarinic, alpha- and beta-adrenoceptors, and of the slow calcium current in the mechanism(s) by which falipamil decreases cardiac automaticity; and (e) suggest possible involvement of a quinidine-sensitive current in this (these) mechanism(s).
authors.affiliation: INSERM U.195, Faculty of Medicine, Clermont-Ferrand, France.
authors.forename: M
authors.initials: M
authors.lastname: Boucher
authors.forename: C
authors.initials: C
authors.lastname: Chassaing
authors.forename: E
authors.initials: E
authors.lastname: Chapuy
authors.forename: P
authors.initials: P
authors.lastname: Duchêne-Marullaz
mesh_terms: D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004285:Dogs; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D007473:Ion Channels / Q000187:drug effects*; D054833:Isoindoles; D008297:Male; D010797:Phthalimides / Q000494:pharmacology*; D010869:Pindolol / Q000494:pharmacology; D011802:Quinidine / Q000494:pharmacology; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D011976:Receptors, Muscarinic / Q000187:drug effects; D013268:Stimulation, Chemical; D014700:Verapamil / Q000494:pharmacology
chemical_list: D002317:Cardiovascular Agents; D007473:Ion Channels; D054833:Isoindoles; D010797:Phthalimides; D011943:Receptors, Adrenergic, beta; D011976:Receptors, Muscarinic; D001285:Atropine; D010869:Pindolol; D014700:Verapamil; D011802:Quinidine; C030532:falipamil